Table 1.
The list of input modeling parameters, including limits of electrophysiological parameters and ion-channel IC50 values used to predict drug effects on the cardiac Action Potentials (APs).
| Action Potential Biomarkers (Parameters) (Lower and Upper Limit) | ||
|---|---|---|
| Parameter | Lower limit | Upper limit |
| Peak Voltage (mV) | 10 | 55 |
| RMP (mV) | −95 | −80 |
| APD 90 (ms) | 180 | 440 |
| APD 50 (ms) | 110 | 350 |
| APD 40 (ms) | 85 | 320 |
| Tri 90–40 (ms) | 50 | 150 |
| Hydroxyzine | ||
| Ion-channel inhibited | IC50 (µM) | Hill coefficient. |
| hERG (IKr) | 0.39 | 1 |
| Nav1.5 (INa) | 13.3 | 1 |
| Cav1.2 (ICa) | 8.6 | 1 |
| Loperamide | ||
| Ion-channel | IC50 (µM) | Hill coefficient |
| hERG (IKr) | 0.3897 | 1.21 |
| Nav1.5 (INa) | 0.526 | 1.11 |
| Cav1.2 (ICa) | 4.084 | 1.64 |
| Free Therapeutic Plasma Concentration (FTPC) | ||
| Loperamide | 0.25 nM | |
| Hydroxyzine | 0.013 µM | |
RMP: resting membrane potential, APD40, APD50, APD90: the duration of the action potential at 40%, 50%, and 90% repolarization.